List view / Grid view
Two separate studies show that IgG serotype antibodies targeting the SARS-CoV-2 spike protein are still detectable in patient’s blood and saliva after 90 days.
A research team has developed a potentially universal flu vaccine that has demonstrated success in mice.
8 October 2020 | By SPT Labtech
In this on-demand webinar, we explored the various methods of COVID-19 testing: qPCR, COVID-seq, antigen and antibody detection, and others. Coupling these assays with low volume, high speed automation has made great strides toward achieving the high-throughput testing essential to ending this pandemic.
An analysis of SARS-CoV-2 has allowed researchers to identify epitopes recognised by a large fraction of COVID-19 patients, with 10 that could be targeted by antibodies.
Pre-clinical studies in cells and hamsters have shown that potent antibodies from COVID-19 patients can prevent infection from SARS-CoV-2.
Scientists reveal that some patients who develop severe COVID-19 symptoms mount ineffective immune responses due to a lack of type I interferons, either through genetic mutation or inactivation by auto-reactive antibodies.
Helping in the race to identify effective neutralising antibodies against the spike protein of SARS-CoV-2 virus as the COVID-19 global death rate continues to rise.
Discover how absorbance detection works as well as different types of absorbance-based assay applications that scientists can utilise for their research.
Molecular Devices helps Recursion produce the largest publicly available set of human cellular morphological data for COVID-19 therapeutic research.
The component, now developed into a drug called Ab8, was highly effective at treating and preventing SARS-CoV-2 infection in animal models.
In the continuing battle against COVID-19, researchers now must identify the best candidates for vaccines and convalescent serum therapies against the virus.
In this application note, Fluidic Analytics show that by using MDS on the Fluidity One-W Serum we can accurately detect and characterise the binding affinity of antibodies to virus proteins directly in human serum.
Taylor B Guo, Chief Scientific Officer at I-Mab, describes the potential benefits of bispecific antibodies for cancer therapy and how their dual targeting mechanisms of action may drive their emergence as the next generation of immuno-oncology drugs.
In this article, Aparajita Dubey discusses the role of antibodies in regulating the immune system and highlights key features that need to be considered for drug development and how this can be applied to cancer therapy.
In 2019, the SARS-CoV-2 coronavirus sparked a global pandemic that is likely to continue into 2021. Effective therapeutics that treat the symptoms of the disease and prevent or treat the underlying viral infection are critically required. To meet this need, the global biopharmaceutical industry is evaluating over 50 monoclonal antibody…
